Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.93 USD | -0.25% | +1.81% | +11.97% |
Apr. 25 | Transcript : Aldeyra Therapeutics, Inc. - Special Call | |
Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 162.4 | 266.3 | 232.4 | 407.6 | 206.5 | 233.5 | - | - |
Enterprise Value (EV) 1 | 162.4 | 266.3 | 18.08 | 407.6 | 206.5 | 233.5 | 233.5 | 233.5 |
P/E ratio | -2.59 x | -6.18 x | -3.74 x | -6.57 x | -5.48 x | -78.6 x | -10.4 x | -42.5 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | 8.21 x | 9.42 x | 4.09 x |
EV / Revenue | - | - | - | - | - | 8.21 x | 9.42 x | 4.09 x |
EV / EBITDA | - | - | -4.15 x | -6.53 x | - | -6.08 x | -5.51 x | -8.2 x |
EV / FCF | - | -7.1 x | -4.13 x | -8.04 x | -4.93 x | -6.71 x | -3.96 x | -5.05 x |
FCF Yield | - | -14.1% | -24.2% | -12.4% | -20.3% | -14.9% | -25.3% | -19.8% |
Price to Book | - | 4.46 x | 1.13 x | - | - | - | - | - |
Nbr of stocks (in thousands) | 27,953 | 38,820 | 58,092 | 58,560 | 58,822 | 59,414 | - | - |
Reference price 2 | 5.810 | 6.860 | 4.000 | 6.960 | 3.510 | 3.930 | 3.930 | 3.930 |
Announcement Date | 3/12/20 | 3/11/21 | 3/17/22 | 3/9/23 | 3/7/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | 28.43 | 24.78 | 57.03 |
EBITDA 1 | - | - | -55.96 | -62.42 | - | -38.4 | -42.36 | -28.49 |
EBIT 1 | -63.07 | -36.42 | -56.22 | -62.68 | -42.79 | -23.13 | -45.83 | -15.73 |
Operating Margin | - | - | - | - | - | -81.37% | -184.95% | -27.58% |
Earnings before Tax (EBT) 1 | -62.14 | -38.03 | -57.78 | -62.02 | -37.54 | -15.99 | -41.96 | -6.194 |
Net income 1 | -60.83 | -37.55 | -57.78 | -62.02 | -37.54 | -1.576 | -23.04 | -6.372 |
Net margin | - | - | - | - | - | -5.54% | -93% | -11.17% |
EPS 2 | -2.240 | -1.110 | -1.070 | -1.060 | -0.6400 | -0.0500 | -0.3775 | -0.0925 |
Free Cash Flow 1 | - | -37.49 | -56.29 | -50.7 | -41.92 | -34.8 | -59 | -46.2 |
FCF margin | - | - | - | - | - | -122.41% | -238.12% | -81.01% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Announcement Date | 3/12/20 | 3/11/21 | 3/17/22 | 3/9/23 | 3/7/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | 1.2 | - | - | 18.8 |
EBITDA 1 | - | - | - | - | - | - | - | - | - | - | -7.442 | -8.827 | -10.47 | -11.66 |
EBIT 1 | -15.44 | -15.4 | -16.48 | -17.71 | -14.78 | -13.7 | -16.8 | -10.34 | -9.55 | -6.098 | -8.102 | -9.072 | -10.47 | -11.33 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | -675.15% | - | - | -60.28% |
Earnings before Tax (EBT) 1 | -15.79 | -15.75 | -16.79 | -17.78 | -14.55 | -12.9 | -15.62 | -8.987 | -8.187 | -4.753 | -7.079 | -7.936 | -9.261 | -10.43 |
Net income 1 | -15.79 | -15.75 | -16.79 | -17.78 | -14.55 | -12.9 | -15.62 | -8.987 | -8.187 | -4.753 | -5.801 | -7.962 | -9.64 | 27.71 |
Net margin | - | - | - | - | - | - | - | - | - | - | -483.43% | - | - | 147.41% |
EPS 2 | -0.2700 | -0.2700 | -0.2900 | -0.3000 | -0.2500 | -0.2200 | -0.2700 | -0.1500 | -0.1400 | -0.0800 | -0.0967 | -0.1300 | -0.1600 | 0.4280 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 10/28/21 | 3/17/22 | 5/5/22 | 8/5/22 | 11/10/22 | 3/9/23 | 5/4/23 | 8/3/23 | 11/3/23 | 3/7/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | 214 | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -37.5 | -56.3 | -50.7 | -41.9 | -34.8 | -59 | -46.2 |
ROE (net income / shareholders' equity) | - | - | -43.6% | -34.8% | -27.7% | -39% | -27.6% | -13.4% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | 1.540 | 3.540 | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | 0.01 | - | 0.01 | 0.02 | - | - | 2.8 | 3.3 |
Capex / Sales | - | - | - | - | - | - | 11.3% | 5.79% |
Announcement Date | 3/12/20 | 3/11/21 | 3/17/22 | 3/9/23 | 3/7/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.97% | 233M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ALDX Stock
- Financials Aldeyra Therapeutics, Inc.